Quarterly report · Q3
4544.TEDINET S100SUU5
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥177.5bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥260.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥201.0bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | −¥1.1bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥23.7bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | −¥2.9bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥23.2bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | −¥3.2bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥25.8bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥3.3bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥18.8bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥3.3bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥18.8bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥284.1bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥297.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥281.9bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥140.9bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥147.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥143.2bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥150.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥153.3bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥40.4bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥44.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥40.4bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥44.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥30.5bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥9.4bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥32.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥19.2bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥9.2bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥29.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥24.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥4.6bn | 2023-04-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥10.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-58.78 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-26.78 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥275.52 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥331.22 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥57.35 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥275.5 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥331.19 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 50.4% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.4% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥4.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥4.5bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | −¥4.6bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥110.2bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥110.0bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥214m |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | −¥8.6bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥50.7bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥46.4bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥4.3bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥11.0bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥21.1bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥21.1bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥4m |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥938m |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥182.0bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥177.5bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥4.5bn |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥3.4bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥6.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥6.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥3.3bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥124.9bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥124.7bn |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥212m |
| jpcrp040300-q3r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.7bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥61.6bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥55.6bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥5.9bn |
| jpcrp040300-q3r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥23.5bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥20.7bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥20.6bn |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥15m |
| jpcrp040300-q3r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥825m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥207.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥201.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥26.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 485
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)PwC Japan有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)鵜 飼 千 恵 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)谷 口 寿 洋 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 200963000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 177511000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 260908000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 23208000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | -2863000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 22010000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 18845000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | -3345000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 15676000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 20245000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 470000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 16970000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 153318000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 143171000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 150047000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 281883000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 284076000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 297924000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 331.22 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | -58.78 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 275.52 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | 331.19 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 275.50 | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.544 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.504 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.503 | |
| Net cash provided by used in operating activities (5-year summary) | Prior1YTDDuration | 19188000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYTDDuration | 9375000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 32535000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YTDDuration | -24859000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYTDDuration | -9159000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -29583000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YTDDuration | -10854000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYTDDuration | -4575000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -5757000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1QuarterInstant | 30480000000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentQuarterInstant | 40402000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 44185000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 57.35 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | -26.78 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 57473822 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 57473822 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 57473822 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 57473822 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |